# Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

> **NCT03483961** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 445 (actual)

## Conditions studied

- Chikungunya Virus Infection

## Interventions

- **BIOLOGICAL:** CHIKV VLP/unadjuvanted
- **BIOLOGICAL:** CHIKV VLP/adjuvanted
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03483961
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-18
- **Primary completion:** 2020-09-14
- **Final completion:** 2020-09-21
- **Target enrollment:** 445 (ACTUAL)
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03483961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03483961, "Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03483961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*